Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment

Research output: Contribution to journalArticlepeer-review

Abstract

We discuss our recent findings on the increase, in chronic myeloid leukemia patients treated with imatinib, of B1 lymphocytes producing IgM anti-O-linked sugars expressed by leukemic cells, paralleled by increased B-stimulating cytokines. We propose that one important effect of imatinib treatment is due to the remodelling of bone marrow microenvironment.

Original languageEnglish
Pages (from-to)214-216
Number of pages3
JournalOncoImmunology
Volume1
Issue number2
DOIs
Publication statusPublished - 2012

Keywords

  • B1 cells
  • Bone morphogenetic proteins
  • Chronic myelogenous leukemia
  • SDF-1 BAFF

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint

Dive into the research topics of 'Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment'. Together they form a unique fingerprint.

Cite this